Additionally, we have detailed the rationale and evidence supporting the application of select molecularly targeted radiosensitizers such as HSP90 inhibitors, tyrosine kinase inhibitors, and mTOR inhibitors in the treatment of prostate cancer. The gene discussed is HSP90AA1; the disease is prostate carcinoma.